Cancer Therapy : Preclinical RG 7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response

@inproceedings{Yin2013CancerT,
  title={Cancer Therapy : Preclinical RG 7212 Anti-TWEAK mAb Inhibits Tumor Growth through Inhibition of Tumor Cell Proliferation and Survival Signaling and by Enhancing the Host Antitumor Immune Response},
  author={Xuefeng Yin and Leopoldo L. Luistro and Hua Zhong and Melissa Smith and Tom Nevins and Kathleen J Schostack and Holly Hilton and Tai-An Lin and Theresa Truitt and Denise A. Biondi and XiaoqianWang and Kathryn Packman and Jim Rosinski and Windy Berkofsky-Fessler and Jian-Ping Tang and Saumya Pant and David Geho and Suzana M Vega-Harring and Mark Demario and Hy Levitsky and Mary Simcox},
  year={2013}
}
Purpose:Toexplore the role of TWEAK in tumor growthandantitumor immune response and the activity and mechanism of RG7212, an antagonistic anti-TWEAK antibody, in tumor models. Experimental Design: TWEAK-induced signaling and gene expression were explored in tumor cell lines and inhibition of these effects and antitumor efficacy with RG7212 treatment was assessed in human tumor xenograft-, patient-derived xenograft, and syngeneic tumor models and phase I patients. Genetic features correlated… CONTINUE READING